Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Buy" by Brokerages

Key Points

• Sana Biotechnology, Inc. has received a consensus "Buy" rating from analysts, with an average 1-year price target set at $8.00.
• Several institutional investors have significantly increased their stakes in Sana Biotechnology, with the firm now being 88.23% owned by institutional investors.
• As of the latest trading session, Sana Biotechnology's shares opened at $2.98 and have a 52-week low of $1.26 and a high of $7.30.

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) has received a consensus recommendation of "Buy" from the six ratings firms that are covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $8.00.

A number of equities analysts recently commented on SANA shares. Morgan Stanley started coverage on shares of Sana Biotechnology in a research report on Thursday, July 3rd. They set an "overweight" rating and a $12.00 price target on the stock. JMP Securities reaffirmed a "market outperform" rating and set a $5.00 price target on shares of Sana Biotechnology in a research report on Tuesday, June 24th.

Hedge Funds Weigh In On Sana Biotechnology

Hedge funds have recently bought and sold shares of the business. Millennium Management LLC increased its holdings in Sana Biotechnology by 604.8% in the 4th quarter. Millennium Management LLC now owns 728,901 shares of the company's stock valued at $1,188,000 after buying an additional 625,481 shares during the period. Two Sigma Advisers LP lifted its holdings in shares of Sana Biotechnology by 677.0% during the 4th quarter. Two Sigma Advisers LP now owns 209,000 shares of the company's stock worth $341,000 after acquiring an additional 182,100 shares during the period. Two Sigma Investments LP lifted its holdings in shares of Sana Biotechnology by 228.4% during the 4th quarter. Two Sigma Investments LP now owns 480,298 shares of the company's stock worth $783,000 after acquiring an additional 334,042 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Sana Biotechnology by 10.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 279,282 shares of the company's stock worth $455,000 after acquiring an additional 25,383 shares during the period. Finally, Ameriprise Financial Inc. bought a new stake in shares of Sana Biotechnology during the 4th quarter worth approximately $29,000. 88.23% of the stock is owned by institutional investors.

Sana Biotechnology Stock Performance

NASDAQ:SANA traded down $0.06 during mid-day trading on Friday, reaching $2.97. 1,381,060 shares of the company's stock were exchanged, compared to its average volume of 5,776,460. Sana Biotechnology has a one year low of $1.26 and a one year high of $7.30. The firm has a market capitalization of $705.11 million, a PE ratio of -2.78 and a beta of 1.88. The business's fifty day simple moving average is $3.72 and its two-hundred day simple moving average is $2.70.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.04. As a group, equities research analysts forecast that Sana Biotechnology will post -1.16 EPS for the current year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.